Daidzein
Soy isoflavone with oestrogenic activity (phytoestrogen) — binds oestrogen receptors ERα and ERβ with preference for ERβ. Metabolised by gut bacteria to equol (more potent oestrogenic metabolite) in approximately 30-50% of people. Used for menopausal symptoms, bone health, and cardiovascular risk.
How it works (mechanism of action)
Acts on cellular signalling pathways relevant to the documented clinical indications. Contains bioactive compounds with enzyme-modulating, receptor-binding, or antioxidant properties studied in peer-reviewed literature.
HORMONE-SENSITIVE CONDITIONS: Contraindicated in oestrogen receptor-positive (ER+) breast cancer, endometrial cancer, uterine fibroids, endometriosis — oestrogenic activity may stimulate tumour growth. Thyroid: may interfere with thyroid hormone synthesis — caution in hypothyroidism. Drug interaction: tamoxifen (may antagonise). Fertility: high doses may affect menstrual cycle. Male fertility: high doses may reduce testosterone.